Treace Medical Concepts, Inc. (TMCI)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1630627 · fiscal year ends in Dec
Closing price $4.42 on 30 Oct 2026; 52-week range $1.20 to $6.59.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $205.3M
- Revenue growth
- -4.0%
- Net income, last twelve months
- -$59.5M
- Earnings per share
- -$0.93
- Gross margin
- 79.5%
- Operating margin
- -26.2%
- Net margin
- -29.0%
- Free cash flow
- -$25.0M
- Return on equity
- -87.9%
- Market value
- $287.1M
- Cash
- $12.6M
- Debt
- $56.0M
- Debt to equity
- 0.83
- Shares outstanding
- 65.0M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $212.7M | -$54.2M | -$59.0M | -$0.93 | -$29.5M | 10-K filed 27 Feb 2026 |
| FY2024 | 31 Dec 2024 | $209.4M | -$55.7M | -$55.7M | -$0.90 | -$48.8M | 10-K filed 27 Feb 2025 |
| FY2023 | 31 Dec 2023 | $187.1M | -$51.4M | -$49.5M | -$0.81 | -$46.0M | 10-K filed 27 Feb 2024 |
| FY2022 | 31 Dec 2022 | $141.8M | -$34.8M | -$42.8M | -$0.77 | -$45.5M | 10-K filed 8 Mar 2023 |
| FY2021 | 31 Dec 2021 | $94.4M | -$16.5M | -$20.6M | -$0.43 | -$19.9M | 10-K filed 4 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $45.4M | -$15.9M | -$0.24 |
| Q1 FY2026 | 31 Mar 2026 | $47.2M | -$18.0M | -$0.28 |
| Q4 FY2025 | 31 Dec 2025 | $62.5M | -$9.4M | -$0.15 |
| Q3 FY2025 | 30 Sep 2025 | $50.2M | -$16.3M | -$0.26 |
| Q2 FY2025 | 30 Jun 2025 | $47.4M | -$17.4M | -$0.28 |
| Q1 FY2025 | 31 Mar 2025 | $52.6M | -$15.9M | -$0.25 |
| Q4 FY2024 | 31 Dec 2024 | $68.7M | -$501.0K | -$0.01 |
| Q3 FY2024 | 30 Sep 2024 | $45.1M | -$15.4M | -$0.25 |
Company events
The newest 8-K filings of 47 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 7 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 20 May 2026 | 8-K | Shareholder vote | 5.07, 9.01 |
| 8 May 2026 | 8-K | Results | 2.02, 9.01 |
| 9 Apr 2026 | 8-K | Results, Leadership change, Investor update | 2.02, 5.02, 7.01 |
| 27 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 13 Jan 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 18 Dec 2025 | 8-K | Material agreement, Agreement ended, New debt, Shareholder rights change, Investor update, Other events | 1.01, 1.02, 2.03, 3.03, 7.01, 8.01, 9.01 |
| 6 Nov 2025 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 7 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 21 May 2025 | 8-K | Shareholder vote | 5.07, 9.01 |
| 8 May 2025 | 8-K | Results | 2.02, 9.01 |
| 7 Apr 2025 | 8-K | Leadership change | 5.02, 9.01 |
Every filing
The newest filings with the SEC of 110 held.
| Filed | Form | Period |
|---|---|---|
| 7 Aug 2026 | 10-Q | 30 Jun 2026 |
| 7 Aug 2026 | 8-K | 7 Aug 2026 |
| 20 May 2026 | 8-K | 19 May 2026 |
| 8 May 2026 | S-8 | – |
| 8 May 2026 | 10-Q | 31 Mar 2026 |
| 8 May 2026 | 8-K | 8 May 2026 |
| 9 Apr 2026 | 8-K | 8 Apr 2026 |
| 6 Apr 2026 | ARS | 31 Dec 2025 |
| 6 Apr 2026 | DEFA14A | – |
| 6 Apr 2026 | DEF 14A | 3 Apr 2026 |
| 27 Feb 2026 | 10-K | 31 Dec 2025 |
| 27 Feb 2026 | 8-K | 27 Feb 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 24 Aug 2026 | Treace John T., Chief Executive Officer | Purchase | 11,000 | $4.34 | $47.7K | 7,404,383 | 24 Aug 2026 |
| 21 Aug 2026 | Treace John T., Chief Executive Officer | Purchase | 5,000 | $4.35 | $21.7K | 7,393,383 | 24 Aug 2026 |
| 20 Aug 2026 | Treace John T., Chief Executive Officer | Purchase | 39,944 | $4.44 | $177.2K | 7,388,383 | 24 Aug 2026 |
| 11 Jun 2026 | Treace John T., Chief Executive Officer | Purchase | 22,887 | $4.04 | $92.5K | 7,376,150 | 11 Jun 2026 |
| 10 Jun 2026 | Treace John T., Chief Executive Officer | Purchase | 29,430 | $4.02 | $118.4K | 7,353,263 | 11 Jun 2026 |
| 1 Jun 2026 | Treace John T., Chief Executive Officer | Purchase | 50,000 | $3.56 | $177.9K | 7,323,833 | 1 Jun 2026 |
| 28 May 2026 | Treace John T., Chief Executive Officer | Purchase | 61,202 | $3.02 | $184.8K | 7,273,833 | 28 May 2026 |
| 27 May 2026 | Treace John T., Chief Executive Officer | Purchase | 49,810 | $2.87 | $143.2K | 7,212,631 | 28 May 2026 |
| 26 May 2026 | Treace John T., Chief Executive Officer | Purchase | 4,508 | $2.79 | $12.6K | 7,162,821 | 28 May 2026 |
| 14 May 2026 | Treace John T., Chief Executive Officer | Purchase | 61,750 | $2.62 | $161.5K | 7,158,313 | 14 May 2026 |
| 13 May 2026 | Treace John T., Chief Executive Officer | Purchase | 49,013 | $2.46 | $120.5K | 7,096,563 | 14 May 2026 |
| 12 May 2026 | Treace John T., Chief Executive Officer | Purchase | 43,000 | $2.17 | $93.5K | 7,047,550 | 14 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Armistice Capital, LLC | 13G amended | 9.79% | 6.4M |
| 12 Aug 2026 | John T. Treace | 13G amended | 19.2% | 12.5M |
| 30 Jul 2026 | BlackRock, Inc. | 13G amended | 1.5% | 959.3K |
| 15 May 2026 | Armistice Capital, LLC | 13G amended | 9.85% | 6.4M |
| 14 May 2026 | BANK OF AMERICA CORP /DE/ | 13G | 5.5% | 3.5M |
| 17 Feb 2026 | Armistice Capital, LLC | 13G amended | 9.99% | 6.4M |
| 12 Feb 2026 | Gagnon Securities LLC | 13G amended | 9.6% | 6.1M |
| 9 Feb 2026 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 13G amended | 1.8% | 1.1M |
| 14 Nov 2025 | Armistice Capital, LLC | 13G amended | 9.99% | 6.3M |
| 12 Nov 2025 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 13G | 5.8% | 3.7M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 1.9M | -2.67% | 8.34 |
| 30 Sep 2026 | 2.0M | +13.84% | 8.6 |
| 15 Sep 2026 | 1.7M | +11.26% | 8.46 |
| 31 Aug 2026 | 1.6M | -2.22% | 5.35 |
| 14 Aug 2026 | 1.6M | -6.08% | 2.97 |
| 31 Jul 2026 | 1.7M | -7.87% | 5.47 |
| 15 Jul 2026 | 1.8M | +5.5% | 3.58 |
| 30 Jun 2026 | 1.7M | -46.55% | 1.04 |
Funds that hold it
From each fund's latest Form 13F.
146 funds held it at 30 Jun 2026: 68 added and 32 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Armistice Capital, LLC | 6,364,000 | $25.3M | 0 |
| Bank of America Corp. | 3,305,100 | $13.2M | +90,807 |
| Gagnon Securities LLC | 3,029,543 | $12.1M | -2,172,343 |
| Vanguard Capital Management LLC | 2,028,479 | $8.1M | +566,972 |
| Gagnon Advisors, LLC | 1,534,034 | $6.1M | +1,534,034 |
| AQR Capital Management LLC | 1,497,673 | $6.0M | +435,833 |
| BlackRock, Inc. | 1,380,021 | $5.5M | -1,960,002 |
| Marshall Wace, LLP | 1,328,592 | $5.3M | +1,063,659 |
| CIBC Bancorp USA Inc. | 1,216,044 | $4.8M | -2,309 |
| Acadian Asset Management LLC | 928,177 | $3.7M | -13,116 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B